Is First Tracks Biotherapeutics Inc a good investment? First Tracks Biotherapeutics Inc (TRAX) is currently trading at 47.10 USD. Market analysts have a consensus price target of 75.17 USD. This suggests a potential upside from current levels.
Earnings Schedule: First Tracks Biotherapeutics Inc is expected to release its next earnings report on Feb. 2, 2027. The market consensus estimate for Forward EPS is -3.51.
No, it does not currently pay a dividend.
First Tracks Biotherapeutics Inc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Feb. 2, 2027. The company currently has a trailing EPS of -4.71.
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.
Community Discussion